Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 138 от 154

Активно (без набиране) Фаза 3

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Acute Myeloid Leukemia Myelodysplastic Syndrome With Excess Blasts-2

Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML). Addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy prolongs event-free survival (EFS) and overall survival (OS) in patients with a FLT3 mutation. Gilteritinib is a more potent and more specific inhibitor of mutant FLT3 in comparison to midostaurin and has shown promising clinical activity in AML.

Начало: 20.12.2019 Край: 01.06.2033 Възраст: от 18 г. Лечение

Australia, Belgium, Finland +8 Stichting Hemato-Oncologie voor Volwassenen Nederland NCT04027309

Активно (без набиране) Фаза 1

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT.

Начало: 18.12.2019 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, France +7 GlaxoSmithKline NCT04091126

Активно (без набиране) Фаза 1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

Начало: 17.12.2019 Край: 05.12.2027 Възраст: 18–100 г. Лечение

Australia, Belgium, Canada +9 Amgen NCT04185883

Активно (без набиране)

Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study

Heart Failure Atrial Fibrillation Healthy Ageing Hypercholesterolemia +1

The STAREE-HEART sub-study will examine the effect of statin treatment over a 3-year period compared with placebo on markers of cardiac ageing (myocardial dysfunction). This will include determining global longitudinal strain with transthoracic echocardiography, atrial fibrillation with home measures twice daily for two weeks and changes in biomarkers.

Начало: 12.12.2019 Край: 01.12.2026 Възраст: от 70 г. Превенция

Australia Monash University NCT04536870

Активно (без набиране) Фаза 3

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Cardiovascular Disease and Lipoprotein(a)

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Начало: 12.12.2019 Край: 30.06.2026 Възраст: 18–80 г. Лечение

Argentina, Australia, Belgium +35 Novartis Pharmaceuticals NCT04023552

Активно (без набиране) Фаза 1

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Breast Cancer Advanced Breast Cancer Metastatic Breast Cancer Endometrial Cancer

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

Начало: 10.12.2019 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Belgium, France +5 Eli Lilly and Company NCT04188548

Активно (без набиране)

MAnagement of Systolic Blood Pressure During Thrombectomy by Endovascular Route for Acute Ischaemic STROKE

Stroke Embolus Cerebral Blood Pressure

Stroke is the third most common cause of death in New Zealand and is one of the leading causes of long-term disability at all ages. A life-saving clot retrieval procedure can save lives and prevent disability of patients with ischaemic stroke who get to hospital in time. In New Zealand, 90% of clot retrieval procedures are performed under general anaesthesia. Many anaesthetic drugs can affect blood pressure (BP) and blood flow within the brain. Increasing BP during the procedure could provide additional benefits in this devastating disease. A large trial is needed to investigate BP management during clot retrieval.

Начало: 28.11.2019 Край: 28.02.2026 Възраст: от 18 г. Лечение

Australia, New Zealand Auckland City Hospital NCT05645861

Активно (без набиране) Фаза 1/2

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

Multiple Myeloma

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Начало: 26.11.2019 Край: 11.03.2027 Възраст: от 18 г. Лечение

Australia, Canada, France +5 GlaxoSmithKline NCT07217119

Активно (без набиране) Фаза 3

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.

Начало: 26.11.2019 Край: 02.12.2026 Възраст: 18–85 г. Лечение

Argentina, Australia, Belgium +26 Alnylam Pharmaceuticals NCT04153149

Активно (без набиране) Фаза 2

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

Advanced Solid Tumor

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). It will also evaluate ORR in pediatric participants with advanced solid tumors and FGFR alterations.

Начало: 20.11.2019 Край: 31.12.2026 Възраст: от 6 г. Лечение

Argentina, Australia, Belgium +12 Janssen Research & Development, LLC NCT04083976

Активно (без набиране)

Surveillance AFter Extremity Tumor surgerY

Soft Tissue Sarcoma Lung Metastases

Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is an integral element of patient care. However, the detection of metastases does not necessarily affect long-term survival and may negatively impact quality of life. Surveillance strategies have not been well researched and have been identified as the top research priority in the extremity sarcoma field. Using a 2X2 factorial design to maximize efficiency and reduce overall trial costs, the SAFETY trial randomized 310 extremity soft-tissue sarcoma (STS) patients to determine the effect of surveillance strategy on overall patient survival after surgery for a STS of the extremity by comparing the effectiveness of both surveillance frequency (every 3 vs. every 6 months) and imaging modality (CT scans vs. chest radiographs).

Начало: 19.11.2019 Край: 01.12.2027 Възраст: от 18 г. Превенция

Argentina, Australia, Belgium +10 McMaster University NCT03944798

Активно (без набиране) Фаза 2

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

B-cell Non-Hodgkin Lymphoma (B-NHL)

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works in the body * How much odronextamab is present in the blood

Начало: 13.11.2019 Край: 15.12.2028 Възраст: от 18 г. Лечение

Australia, Canada, China +11 Regeneron Pharmaceuticals NCT03888105

Активно (без набиране)

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

Mitral Regurgitation Functional Mitral Valve Disease Cardiovascular Diseases

To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation

Начало: 13.11.2019 Край: 01.11.2026 Възраст: от 18 г. Устройства

Australia, United States Boston Scientific Corporation NCT04147884

Активно (без набиране) Фаза 3

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

Haemophilia A Without Inhibitors Haemophilia B Without Inhibitors

This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group participants will get study medicine from the start of the study. In the other group participants will continue with their normal medicine and get study medicine after 6 months. Which treatment the participant gets is decided by chance. Participants who usually take medicine to prevent bleeds (prophylaxis treatment) or who are already being treated with concizumab (study medicine) will receive the study medicine from the start of the study. Participants will have to inject themselves with the study medicine 1 time every day under the skin. This can be done at home. The study doctor will hand out the medicine in the form of a pen-injector. The pen-injector will contain the study medicine. The study will last for up to 8 years. The length of time the participant will be in the study depends on when they agreed to take part and when the medicine is available for purchase in their country (or 31 December 2027 at the latest). The time between visits will be approximately 4 weeks for the first 6 to 12 months depending on the group participants are in, and approximately 8 weeks for the rest of the study. If the participant attends extra visits due to the prescription medicine not being available for purchase in their country, these will be 14 weeks apart. Participants will be asked to record information in an electronic diary during the study and may also be asked to wear an activity tracker.

Начало: 13.11.2019 Край: 21.02.2028 Възраст: от 12 г. Лечение

Algeria, Australia, Bosnia and Herzegovina +27 Novo Nordisk A/S NCT04082429

Активно (без набиране) Фаза 2

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is very low, it's called molecular remission. TKIs are a type of medication that help keep this level low. However, after being in molecular remission for a specific amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is not yet known whether stopping tyrosine kinase inhibitors will help patients with chronic myeloid leukemia in chronic phase continue or re-achieve molecular remission.

Начало: 08.11.2019 Край: 30.06.2026 Възраст: до 25 г. Лечение

Australia, Canada, Puerto Rico +1 Children's Oncology Group NCT03817398

Активно (без набиране) Фаза 3

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

Начало: 05.11.2019 Край: 30.07.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +19 Bristol-Myers Squibb NCT04025879

Активно (без набиране) Фаза 4

Pediatric Long-Term Follow-up and Rollover Study

Diffuse Astrocytoma Anaplastic Astrocytoma Astrocytoma Oligodendroglioma, Childhood +19

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

Начало: 04.11.2019 Край: 05.11.2026 Възраст: 1–99 г. Лечение

Argentina, Australia, Belgium +15 Novartis Pharmaceuticals NCT03975829

Активно (без набиране)

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Metastatic Tumors

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) alone, on overall survival, progression-free survival, toxicity, and quality of life. An integrated economic evaluation will determine the cost per quality of life year gained using SABR (vs. SOC) and a translational component will enable identification of predictive/prognostic biomarkers of the oligometastatic state.

Начало: 01.11.2019 Край: 31.12.2030 Възраст: от 18 г. Лечение

Australia, Canada, Ireland +1 British Columbia Cancer Agency NCT03862911

Активно (без набиране) Фаза 3

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Melanoma

The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.

Начало: 28.10.2019 Край: 29.06.2027 Възраст: от 12 г. Лечение

Australia, Belgium, Canada +14 Bristol-Myers Squibb NCT04099251

Активно (без набиране) Фаза 3

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in the Open-Label Period, if regionally applicable, until mavorixafor becomes commercially available, or until the study is terminated by the Sponsor.

Начало: 24.10.2019 Край: 01.12.2025 Възраст: от 12 г. Лечение

Australia, Denmark, France +9 X4 Pharmaceuticals NCT03995108

1 … 136 137 138 139 140 … 154